STAT3 and mature T-cell and NK-cell non-Hodgkin lymphoma: There are several ongoing clinical stageSTAT3 inhibitors currently being investigated in advanced tumor patients.For instance, Napabucasin (BBI608) is an orally available STAT3 andcancer cell stemness inhibitor,39 whichhas finished phase III studies in patients with advanced tumor incombination with standard chemotherapies.40 In TNBC and PTCL models, oral administration of YY002 demonstratedsuperior antitumor efficacy compared to BBI608.